{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:31Z","timestamp":1790727031268,"version":"4.1.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Arterial hypertension represents the most important cardiovascular risk factor with a direct responsibility for a large share of cardiovascular mortality and morbidity in the world. Despite the wide availability of antihypertensive therapies with documented effectiveness, blood pressure control still remains largely unsatisfactory in large segments of the population. Guidelines for the management of arterial hypertension suggest the preferential use of five classes of drugs\u2014angiotensin-converting enzyme inhibitors, angiotensin II type I receptor inhibitors, calcium channel blockers, thiazide\/thiazide-like diuretics, and beta-blockers\u2014recommending the use of combination therapy, preferably in pre-established combinations, for the majority of hypertensive patients. The evidence of a non-negligible heterogeneity in the response to different antihypertensive drugs in different patients suggests the opportunity for personalization of treatment. The notable phenotypic heterogeneity of the population of hypertensive patients in terms of genetic structure, behavioural aspects, exposure to environmental factors, and disease history imposes the need to consider all the potential determinants of the response to a specific pharmacological treatment. The progressive digitalization of healthcare systems is making enormous quantities of data available for machine learning systems which will allow the development of management algorithms for truly personalized antihypertensive therapy in the near future.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae019","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:39:46Z","timestamp":1713353986000},"page":"i60-i63","source":"Crossref","is-referenced-by-count":5,"title":["Is the response to antihypertensive drugs heterogeneous? Rationale for personalized approach"],"prefix":"10.1093","volume":"26","author":[{"given":"Mario","family":"Muselli","sequence":"first","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L'Aquila , L\u2019Aquila"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Bocale","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Agostino Gemelli University Hospital Foundation Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Catholic University of the Sacred Heart , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Necozione","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L'Aquila , L\u2019Aquila"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L'Aquila , L\u2019Aquila"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2024041706394494600_suae019-B1","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2024041706394494600_suae019-B2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2024041706394494600_suae019-B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41569-020-00466-4","article-title":"Genomics of hypertension: the road to precision medicine","volume":"18","author":"Padmanabhan","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2024041706394494600_suae019-B4","author":"WHO Global report on hypertension"},{"key":"2024041706394494600_suae019-B5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/01.hjh.0000187261.40190.2e","article-title":"Rate and determinants of 10-year persistence with antihypertensive drugs","volume":"23","author":"Van Wijk","year":"2005","journal-title":"J Hypertens"},{"key":"2024041706394494600_suae019-B6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/HYPERTENSIONAHA.120.16418","article-title":"Hypertension control in the United States 2009\u20132018: factors underlying falling control rates during 2015 to 2018 across age- and race-ethnicity groups","volume":"78","author":"Egan","year":"2021","journal-title":"Hypertens"},{"key":"2024041706394494600_suae019-B7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2023.3322","article-title":"Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial","volume":"329","author":"Sundstr\u00f6m","year":"2023","journal-title":"JAMA"},{"key":"2024041706394494600_suae019-B8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/HYPERTENSIONAHA.122.20458","article-title":"Clinical utility of short-term blood pressure measure to inform long-term blood pressure management","volume":"80","author":"Wang","year":"2023","journal-title":"Hypertens"},{"key":"2024041706394494600_suae019-B9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1471-2369-14-201","article-title":"Difference in blood pressure response to ACE-inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials","volume":"14","author":"Peck","year":"2013","journal-title":"BMC Nephrol"},{"key":"2024041706394494600_suae019-B10","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1177\/2047487319856733","article-title":"Phenomapping of subgroups in hypertensive patients using unsupervised data-driven cluster analysis: an exploratory study of the SPRINT trial","volume":"26","author":"Yang","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2024041706394494600_suae019-B11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12911-023-02137-z","article-title":"Personalized hypertension treatment recommendations by a data-driven model","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"key":"2024041706394494600_suae019-B12","doi-asserted-by":"crossref","first-page":"1070115","DOI":"10.3389\/fphys.2022.1070115","article-title":"Mathematical modeling of antihypertensive therapy","volume":"13","author":"Kutumova","year":"2022","journal-title":"Front Physiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_1\/i60\/57239707\/suae019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_1\/i60\/57239707\/suae019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:39:52Z","timestamp":1713353992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/26\/Supplement_1\/i60\/7646217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":12,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae019","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4]]}}}